Blacksmith Medicines, a biotechnology company focused on creating medicines for immuno-oncology, agreed to merge with Forge Therapeutics, a biotechnology company. Financial terms are not disclosed. "We are excited to unveil the merger of Blacksmith and Forge, which we believe will be transformational for both companies. Prospects are very bright for the new Blacksmith, as we are now able to expand our metalloenzyme platform, advance our internal and partnered programs, and create increased value for our shareholders by discovering first-in-class and best-in-class medicines. Our target strategy is to focus on metalloenzymes of significant unmet need and high pharma interest, targets with validated biology that have been challenging to drug due to chemistry limitations that we can solve with our platform," Zachary Zimmerman, Blacksmith CEO and Co-Founder.